Loading...
XNAS
FENC
Market cap208mUSD
Dec 05, Last price  
7.55USD
1D
-2.96%
1Q
-16.11%
Jan 2017
252.80%
IPO
229.69%
Name

Fennec Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:FENC chart
P/E
—
P/S
4.38
EPS
—
Div Yield, %
—
Shrs. gr., 5y
6.53%
Rev. gr., 5y
%
Revenues
48m
+123.69%
000000000000000170,00001,535,00021,252,00047,538,000
Net income
-436k
L-97.28%
-19,245,000-19,103,000-13,357,000-13,600,000-3,012,000-7,823,0004,685,000-5,163,0001,845,000-2,176,000-659,000-2,789,000-7,046,000-9,888,000-12,460,000-17,922,000-17,456,000-24,839,000-16,045,000-436,000
CFO
27m
P
-12,261,000-13,475,000-13,303,000-10,808,000-4,688,000-1,928,000-3,226,000-2,994,000-2,210,000-1,699,000-1,862,000-2,124,000-3,641,000-7,826,000-9,060,000-15,595,000-14,222,000-18,058,000-17,143,00026,980,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
URL
https://fennecpharma.com/
IPO date
Jun 05, 2001
Employees
36
Domiciled in
US
Incorporated in
CA

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT